Spect offers an AI-enabled mobile telemedicine platform and a portable imaging device that lets medical assistants and nurse practitioners capture retinal images and receive diagnostic reports in minutes. The platform returns results in three minutes or less with image gradeability above 95% and is delivered via a SaaS licensing model with no upfront or support cost to customers. Spect's software analyzes images to screen for diabetic retinopathy, glaucoma and age-related macular degeneration, and the company positions retinal data as a predictor of broader health conditions. Its dataset exceeds 1.5 million retinal images and continues to grow, forming the basis for expanded AI capabilities. The company is expanding its executive team and pursuing partnerships with clinics and enterprise health systems to broaden diagnostic access. Spect has acknowledged support from Y Combinator, Johnson & Johnson Innovation – JLABS, Medtech Innovator, and StartX.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2021